Galderma, a pioneer in the dermatology field and listed as SIX: GALD, has received approval from the U.S. FDA for Restylane Contour to treat temple hollowing in individuals aged 21 and above. This approval complements its existing authorizations for cheek augmentation and midface contour insufficiencies, allowing practitioners to tackle volume loss in crucial facial areas. With the most extensive Injectable Aesthetics product range available, this recent approval aligns with Galderma's goal to address various cosmetic concerns.